Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line ...

Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...

A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical Technology, has discovered the critical mechanism of action of tetrandrine, a ...

The enzyme PARP1 helps repair single-stranded DNA breaks, and its inhibition shows antitumor efficacy in ovarian, breast, prostate and pancreatic cancers involving mutations in BRCA1 or BRCA2. However ...